Sign In
26 Sep 2008 07:00
Fulcrum Pharma plc (the "Company")
Appointment of Non-executive Directors
The Board of Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services company, is pleased to announce that Mr. Ken Lacey and Mr. Frank Condella have joined the board as Non-executive Directors effective immediately.
Commenting on these new appointments to the Board, Sir Charles George, Chairman of Fulcrum Pharma, said, "I am delighted to welcome both Ken and Frank to the Board of Fulcrum Pharma. They bring invaluable experience to Fulcrum Pharma in the areas of Healthcare Consulting, the US environment and of the entire Pharma and Biotechnology Industry."
Mr. Grahame Cook, Chairman Designate of Fulcrum Pharma added, "I am looking forward to Ken and Frank joining the Board and to making valuable contributions to the future of Fulcrum Pharma. Their combined skills and experience of the Industry will assist the Board and Management in building Fulcrum Pharma into a substantial professional services company."
Mr. Condella was, until 1st September 2008, the Chief Executive Officer of SkyePharma PLC and will become a Non-executive Director of SkyePharma PLC on 1st November 2008. He has a distinguished career as a Pharmaceutical Executive in senior roles at Ivax Corporation, F H Faulding and Co and Roche in the UK and the US. Mr. Condella holds an M.B.A. from the Graduate School of Business, Northeastern University in Boston and a B.S. in Pharmacy from the College of Pharmacy and Allied Health, Northeastern University, Boston.
Mr. Lacey was, until 31st December 2006, Global Managing Director for Accenture's Health & Life Sciences (H&LS) Practice working with a broad range of clients in Government, the Pharma Industry and the broader Health and Life Science Industry. Mr. Lacey worked for Accenture, and its predecessor companies for 28 years. Mr. Lacey holds a B.A. degree from Rice University and an M.B.A. from the University of Texas.
Pursuant to Rule 17 of the AIM Rules, the information required to be given in respect of Frank Condella is as follows:
Full name: Frank Charles Condella
Previous names: None
Age: 54
In addition to his directorship of the Company, Frank Condella is, or has been, a director of or partner of the following companies or partnerships, at any time in the previous five years:
Current directorships/partnerships
SkyePharma PLC
SkyePharma Production SAS
SkyePharma (Jersey) Limited
SkyePharma AB
SkyePharma Holding Inc
SkyePharma US Inc
Krypton Limited
Past directorships/partnerships
Norton Healthcare Limited
Thomas Kerfoot & Co Limited
IVAX Pharma GmbH
IVAX International (Luxembourg) Sarl
IVAX Farma BV
IVAX International BV
IVAX Pharma Poland sp z.o.o
Kutnowskie Zaklady Farmaceutyczne
"Polfe" Spolka Akcy Jna
Galena Pharma Limited
IVAX Scandinavia AB
IVAX Pharmaceuticals South Africa (Proprietary) Limited
IVAX Farmaceutici S.r.l
IVAX India (Pvt) Ltd
Becpharm Limited
HN Norton & Co Limited
IVAX Europe Limited
IVAX Finland OY
IVAX Healthcare Limited
IVAX Healthcare UK Limited
IVAX Laboratories Limited
IVAX Laboratories UK Limited
IVAX Pharmaceuticals Limited
IVAX Pharmaceurticals UK Limited
IVAX UK Limited
K Pharmaceuticals Limited
Norton (Waterford) Limited
Norton Healthcare (1998) Limited
Norton Healthcare (1999) Limited
Norton Pharmaceuticals Limited
Pharmexco Limited
Steripak Limited
Waverley Pharmaceutical Limited
Baker Norton Limited
The information required to be given in respect of Ken Lacey is as follows:
Full name: Kenneth Lee Lacey
Previous names: None
Age: 55
In addition to his directorship of the Company, Ken Lacey is, or has been, a director of or partner of the following companies or partnerships, at any time in the previous five years:
Current directorships/partnerships
AVA CAD/CAM Group Limited
Warrington Town Football Club Limited
Lomox Limited
Past directorships/partnerships
Accenture LLP
Under Schedule Two, paragraph g, of the AIM Rules, there is nothing further to disclose.
Enquiries:
Fulcrum Pharma plc:
Dr Frank Armstrong, Chief Executive 07508 010912
Seymour Pierce Ltd:
Jonathan Wright/Matt Thomas 020 7107 8000
Follow the stocks
